IMNM
Immunome, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -12.5% ·
share flow -5.5% ·
net new positions -14.3%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | +1 | 68.26M | $1.45B | +7 | −7 |
| Q1 2026 | 85 | +8 | 69.87M | $1.52B | +12 | −4 |
| Q4 2025 | 77 | -1 | 71.18M | $1.53B | — | −1 |
| Q3 2025 | 17 | 0 | 44.21M | $517.66M | +1 | −1 |
| Q2 2025 | 14 | -2 | 33.29M | $309.62M | — | −2 |
| Q1 2025 | 13 | 0 | 18.78M | $126.42M | +1 | −1 |
| Q4 2024 | 13 | +3 | 9.20M | $97.76M | +3 | — |
| Q3 2024 | 9 | -2 | 5.86M | $85.63M | — | −2 |
| Q2 2024 | 11 | — | 5.95M | $72.02M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 6.17M | — | $57.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | BlackRock ✦ (passive) | 5.77M | — | $53.67M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 3 | Point72 Asset Management ✦ | 4.69M | +7.5% | $43.58M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passive) | 4.52M | — | $42.08M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 5 | PRIMECAP Management ✦ | 3.02M | -11.5% | $28.09M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.98M | -2.9% | $27.73M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 2.52M | -4.5% | $23.44M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.86M | +6.7% | $17.31M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 1.30M | -19.4% | $12.07M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 10 | Wellington Management ✦ | 211.83K | +38.4% | $1.97M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 11 | Millennium Management ✦ | 113.55K | -75.4% | $1.06M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 99.37K | -14.3% | $924,160 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 26.65K | -70.3% | $247,882 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 10.20K | 0.0% | $94,860 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $5.22M | was 0.0% |
| Citadel Advisors | $2.29M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 35.50K shares, $776 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 13.20K sh · $334,224
Director · 11.05K sh · $301,058
Director · 62.29K sh · $1.63M
Director · 10.12K sh · $263,959
Director · 15.25K sh · $397,363
Director · 20.84K sh · $543,090
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology